Md. Code Regs. 10.34.29.04

Current through Register Vol. 51, No. 22, November 1, 2024

Section 10.34.29.04 - Requirements for Participation in Drug Therapy Management

A. In order to enter into a therapy management contract, a pharmacist:

(1) Shall be licensed by and in good standing with the Board of Pharmacy;

(2) Shall possess a Doctor of Pharmacy degree or equivalent training as established in §B of this regulation;

(3) May not have:

(a) A public final order by the Board of Pharmacy disciplining the pharmacist's license within the 5 years immediately before the application is submitted; or

(b) Limitations placed on the pharmacist's license by the Board of Pharmacy in a public order;

(4) Shall possess relevant advanced training as indicated by one of the following:

(a) Certification as a specialist related to the disease state specified by the protocol by:

(i) The Board of Pharmacy Specialties;

(ii) The American Society of Consultant Pharmacist's Certified Geriatric Practitioner certification program; or

(iii) Another credentialing body approved by the Board of Pharmacy; or

(b) Successful completion of:

(i) A residency accredited by the American Society of Health-Systems Pharmacists, a body approved by the Board of Pharmacy or offered by a body accredited by the Accreditation Council for Pharmacy Education;

(ii) A certificate program approved by the Board of Pharmacy;

(iii) A National Association of Boards of Pharmacy credentialing examination; or

(iv) An examination approved by the Board of Pharmacy;

(5) Shall have successfully completed:

(a) 1,000 hours of relevant clinical experience; or

(b) 320 hours in a structured experience program approved by the Board of Pharmacy; and

(6) Shall document training related to the disease state specified in the protocol.

B. A pharmacist who does not possess a Doctor of Pharmacy degree shall document that the pharmacist's training has included the following components:

(1) Designing, implementing, monitoring, evaluating, and modifying or recommending modifications in drug therapy to insure effective, safe, and economical patient care;

(2) Identifying, assessing, and solving medication-related problems, and providing clinical judgments as to the continuing effectiveness of individualized therapeutic plans and intended therapeutic outcomes;

(3) Conducting appropriate physical assessments, evaluating patient problems, and ordering and monitoring medications and laboratory tests in accordance with established standards of practice;

(4) Monitoring patients and patient populations regarding the purposes, uses, effects, and pharmacoeconomics of their medications and related therapy;

(5) Providing emergency first care, including cardiopulmonary resuscitation;

(6) Using clinical data to optimize therapeutic drug regimens; and

(7) Documenting interventions and evaluating pharmaceutical care outcomes.

C. The Board of Pharmacy shall determine whether the pharmacist meets the requirements of §§A and B of this regulation.

D. An authorized prescriber who has entered into a prescriber-pharmacist agreement shall submit to the Boards that regulate the authorized prescriber a copy of:

(1) The prescriber-pharmacist agreement;

(2) Subsequent amendments made to the:

(a) Prescriber-pharmacist agreement; or

(b) Protocols specified in the prescriber-pharmacist agreement; and

(3) Changes to participants of the:

(a) Prescriber-pharmacist agreement; or

(b) Protocols specified in the prescriber-pharmacist agreement.

E. The Boards that regulate the authorized prescriber shall notify the authorized prescriber of any additional information needed within 30 days of the receipt of the submitted information.

F. A licensed pharmacist who has entered into a prescriber-pharmacist agreement shall submit to the Board of Pharmacy a copy of:

(1) The prescriber-pharmacist agreement;

(2) Subsequent amendments made to the:

(a) Prescriber-pharmacist agreement; or

(b) Protocols specified in the prescriber-pharmacist agreement; and

(3) Changes to participants of the:

(a) Prescriber-pharmacist agreement; or

(b) Protocols specified in the prescriber-pharmacist agreement.

G. The Board of Pharmacy shall determine whether a pharmacist added under §F of this regulation meets the requirements of §§A and B of this regulation.

H. The Board of Pharmacy shall notify the pharmacist of any additional information needed within 30 days of the receipt of the submitted information.

Md. Code Regs. 10.34.29.04

Regulation .04 amended effective 43:6 Md. R. 409, eff.3/28/2016